Making long‐acting treatment work: Tracing connections with extended‐release buprenorphine depot through time

Documenti analoghi

• The ‘missing’ in the ‘endgame’ of hepatitis C elimination: A qualitative study in New South Wales, Australia
  di: Carla Treloar, et al.
  Pubblicazione: (2024)
• Provider costs of treating opioid dependence with extended‐release buprenorphine in Australia
  di: Stella Settumba, et al.
  Pubblicazione: (2024)
• Clinical effectiveness of pharmacist administration of long‐acting injectable buprenorphine: Findings from the EPIC‐MATOD study
  di: Elizabeth Grist, et al.
  Pubblicazione: (2024)
• Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open‐label, non‐randomised trial of long‐acting injectable buprenorphine treatment in Australian custodial settings
  di: Bethany White, et al.
  Pubblicazione: (2025)
• Differences in stigma reduction related to injection drug use between people expressing conservative, moderate and progressive values following an online intervention
  di: Theresa Caruana, et al.
  Pubblicazione: (2024)